Important gaps remain in our understanding of the composition of the vaginal virome, its interactions with the bacterial microbiome and the host immune system, and its implications for vaginal homeostasis, human papillomavirus (HPV) persistence, and obstetric outcomes. The vaginal virome is a dynamic component of the female genital ecosystem, comprising eukaryotic viruses, bacteriophages, and endogenous viral elements. Recent evidence suggests that alterations in viral composition and diversity may influence the stability of the vaginal microbiome and mucosal immune responses, thereby increasing susceptibility to clinically relevant disorders. Increased viral diversity has been associated with vaginal dysbiosis, persistent HPV infection, and adverse pregnancy outcomes, including preterm birth. In parallel, bacteriophage-based therapies and recombinant endolysins have shown promise for the selective treatment of bacterial biofilms associated with bacterial vaginosis. The vaginal virome is an integral component of the microbial ecology of the female genital tract. A better understanding of its interactions with the bacterial microbiome and the host immune system may facilitate the development of diagnostic biomarkers and innovative therapeutic strategies for precision medicine in women's health.
Important gaps remain in our understanding of the vaginal virome. Its composition, interactions with the bacterial microbiome and host immune system, and implications for vaginal homeostasis, human papillomavirus (HPV) persistence, and obstetric outcomes remain incompletely defined. The vaginal virome is a dynamic component of the female genital ecosystem. It includes viruses that infect human cells, bacteriophages, and endogenous viral elements. Observational studies have associated altered viral composition or diversity with vaginal dysbiosis, persistent HPV detection, and adverse pregnancy outcomes, including preterm birth. These relationships remain correlative, and causality has not been established. Bacteriophage-based therapies and recombinant endolysins may selectively target bacterial biofilms associated with bacterial vaginosis. However, most applications remain preclinical or in early clinical development. Better characterization of the interactions among viruses, bacteria, epithelial cells, and mucosal immunity may support future diagnostic biomarkers and precision therapeutic strategies in women’s health.